课题基金 / 基金详情

Preclinical evaluation of a gentamicin analog as a treatment for genetic diseases and cancer due to a premature termination codon.

Preclinical evaluation of a gentamicin analog as a treatment for genetic diseases and cancer due to a premature termination codon.
庆大霉素类似物治疗因过早终止密码子导致的遗传性疾病和癌症的临床前评估。
批准号:
335020
负责人:
Roberge Michel
金额:
$10.93万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2015
资助国家:
加拿大
项目状态:
已结题
起止时间:
2015-09-01 至 2016-09-01

项目摘要

项目成果

Roberge Michel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Many genes that cause cancer or rare genetic diseases have a mutation that creates a stop signal within the gene instead of only at the end. The protein made from that gene is therefore truncated at the mutation and cannot function properly, resulting in
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mutation-targeted gene and pharmacological therapies for dystrophic and junctional Epidermolysis Bullosa
  • 批准号:
    367021
  • 项目类别:
    Operating Grants
  • 资助金额:
    $22.25万
  • 财政年份:
    2017
  • 负责人:
    Roberge Michel
  • 依托单位:
Preclinical Development of a novel M2 Channel Inhibitor for the Treatment and Prevention of Influenza
  • 批准号:
    293922
  • 项目类别:
    Operating Grants
  • 资助金额:
    $11.66万
  • 财政年份:
    2013
  • 负责人:
    Roberge Michel
  • 依托单位:
Evaluation of the anticancer activity of a new autophagy-inhibitory drug
  • 批准号:
    194925
  • 项目类别:
    Operating Grants
  • 资助金额:
    $10.42万
  • 财政年份:
    2009
  • 负责人:
    Roberge Michel
  • 依托单位:
海外基金